tiprankstipranks
Kuros Biosciences Ltd. (CSBTF)
OTHER OTC:CSBTF
US Market
CSBTF
Kuros Biosciences
RESEARCH TOOLSreports

Kuros Biosciences (CSBTF) Stock Forecast & Price Target

14 Followers
See the Price Targets and Ratings of:

CSBTF Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Kuros
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CSBTF Stock 12 Month Forecast

Average Price Target

$39.88
▲(66.78% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Kuros Biosciences in the last 3 months. The average price target is $39.88 with a high forecast of $40.49 and a low forecast of $39.26. The average price target represents a 66.78% change from the last price of $23.91.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","26":"$26","31":"$31","36":"$36","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40.490307,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.8768175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.263328,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$39.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,26,31,36,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.525,23.90694669230769,25.288893384615385,26.670840076923078,28.05278676923077,29.434733461538464,30.816680153846153,32.19862684615384,33.580573538461536,34.96252023076923,36.34446692307692,37.726413615384615,39.10836030769231,{"y":40.490307,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.525,23.85975519230769,25.194510384615384,26.529265576923077,27.86402076923077,29.198775961538463,30.533531153846155,31.868286346153845,33.20304153846154,34.53779673076923,35.87255192307693,37.207307115384616,38.542062307692305,{"y":39.8768175,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.525,23.81256369230769,25.100127384615384,26.387691076923076,27.67525476923077,28.96281846153846,30.250382153846154,31.537945846153846,32.82550953846154,34.11307323076923,35.400636923076924,36.688200615384616,37.97576430769231,{"y":39.263328,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.66,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.015,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.79,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.805,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.005,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.525,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.49Average Price Target$39.88Lowest Price Target$39.26
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on CSBTF
Tanya Hansalik
UBS
UBS
$40.49
Buy
69.34%
Upside
Reiterated
07/29/26
Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (Other OTC: CSBTF), Centene (NYSE: CNC) and Incyte (NASDAQ: INCY)
Berenberg Bank Analyst forecast on CSBTF
Christian Ehmann
Berenberg Bank
Berenberg Bank
$39.26
Buy
64.21%
Upside
Initiated
07/07/26
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Kuros Biosciences (CSBTF)
Kepler Capital Analyst forecast on CSBTF
Christophe dombu
Kepler Capital
Kepler Capital
$46.63
Buy
95.00%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (Other OTC: SDZXF) and Kuros Biosciences (Other OTC: CSBTF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on CSBTF
Tanya Hansalik
UBS
UBS
$40.49
Buy
69.34%
Upside
Reiterated
07/29/26
Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (Other OTC: CSBTF), Centene (NYSE: CNC) and Incyte (NASDAQ: INCY)
Berenberg Bank Analyst forecast on CSBTF
Christian Ehmann
Berenberg Bank
Berenberg Bank
$39.26
Buy
64.21%
Upside
Initiated
07/07/26
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Kuros Biosciences (CSBTF)
Kepler Capital Analyst forecast on CSBTF
Christophe dombu
Kepler Capital
Kepler Capital
$46.63
Buy
95.00%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (Other OTC: SDZXF) and Kuros Biosciences (Other OTC: CSBTF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kuros Biosciences

3 Months
Christophe dombuKepler Capital
Success Rate
2/7 ratings generated profit
29%
Average Return
-9.50%
Copying Christophe dombu's trades and holding each position for 3 Months would result in 28.57% of your transactions generating a profit, with an average return of -9.50% per trade.
1 Year
Christophe dombuKepler Capital
Success Rate
0/7 ratings generated profit
0%
Average Return
-29.93%
Copying Christophe dombu's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -29.93% per trade.
2 Years
Christophe dombuKepler Capital
Success Rate
0/7 ratings generated profit
0%
Average Return
-30.40%
Copying Christophe dombu's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -30.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CSBTF Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
2
Buy
2
3
3
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
3
3
1
2
In the current month, CSBTF has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CSBTF average Analyst price target in the past 3 months is 39.88.
Each month's total comprises the sum of three months' worth of ratings.

CSBTF Financial Forecast

CSBTF Earnings Forecast

Next quarter’s earnings estimate for CSBTF is $0.07 with a range of $0.07 to $0.07. The previous quarter’s EPS was $0.11. CSBTF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.00% of the time in the same period. In the last calendar year CSBTF has Performed in-line its overall industry.
Next quarter’s earnings estimate for CSBTF is $0.07 with a range of $0.07 to $0.07. The previous quarter’s EPS was $0.11. CSBTF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.00% of the time in the same period. In the last calendar year CSBTF has Performed in-line its overall industry.

CSBTF Sales Forecast

Next quarter’s sales forecast for CSBTF is $47.60M with a range of $47.60M to $47.60M. The previous quarter’s sales results were $81.03M. CSBTF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 54.79% of the time in the same period. In the last calendar year CSBTF has Performed in-line its overall industry.
Next quarter’s sales forecast for CSBTF is $47.60M with a range of $47.60M to $47.60M. The previous quarter’s sales results were $81.03M. CSBTF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 54.79% of the time in the same period. In the last calendar year CSBTF has Performed in-line its overall industry.

CSBTF Stock Forecast FAQ

What is CSBTF’s average 12-month price target, according to analysts?
Based on analyst ratings, Kuros Biosciences Ltd.’s 12-month average price target is 39.88.
    What is CSBTF’s upside potential, based on the analysts’ average price target?
    Kuros Biosciences Ltd. has 66.78% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CSBTF a Buy, Sell or Hold?
          Kuros Biosciences Ltd. has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Kuros Biosciences Ltd.’s price target?
            The average price target for Kuros Biosciences Ltd. is 39.88. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.49 ,the lowest forecast is $39.26. The average price target represents 66.78% Increase from the current price of $23.91.
              What do analysts say about Kuros Biosciences Ltd.?
              Kuros Biosciences Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of CSBTF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.